10 Top Stem Cell Companies on the NASDAQ

The global stem cell therapy market is expected to experience significant growth over the next few years. Here are the 10 top stem cell companies on the NASDAQ.

Stem cell research and regenerative medicine are growing markets in the life sciences sector, and the top stem cell companies are working hard to make advances.

Stem cells are the building blocks of life, with special capabilities that are particularly important in both the early and later stages of a human’s life cycle.

Human stem cells have the ability to develop into a variety of different cell types in the body, including organ-specific cells, as well as muscle tissue and bone marrow cells; they can even renew themselves.

Stem cells serve as an internal repair system in the body. They can divide without limit to replenish other cells as long as the body is still alive. That said, there’s still a lot of lab work that needs to be done before stem cell products can be used as cell-based therapies or regenerative medicines.

A report from Grand View Research projects that the global stem cell market will reach US$18.4 billion by 2028. The research firm sees “the rising number of stem cell banks, growing focus on increasing therapeutic potential of these, and extensive research for the development of regenerative medicines” as drivers of this market. Further market growth is expected to come from government funding for the development of cellular therapies for cancer.

Research and Markets is even more bullish, estimating that the global stem cell therapy market will grow at a compound annual growth rate of 28 percent from 2020 to 2025, reaching US$20.87 billion.

The report’s authors attribute this growth to the rising prevalence of chronic diseases. “According to a United Nations article, by 2030, the proportion of global deaths due to chronic diseases is expected to increase to 70 (percent) of total deaths. The global burden of chronic diseases is expected to reach about 60 (percent),” states Research and Markets.

Here the Investing News Network profiles the 10 top stem cell companies listed on the NASDAQ. The stocks listed below are in order of market cap size from biggest to smallest, with all numbers and figures current as of August 12, 2021.

1. Moderna (NASDAQ:MRNA)

Market cap: US$158 billion

Biotechnology and pharmaceutical company Moderna is a pioneer in the field of mRNA. The company’s assets include a diverse clinical portfolio of vaccines and therapeutics and a large intellectual property (IP) portfolio in areas including mRNA and lipid nanoparticle formulation; it also has an integrated manufacturing plant that allows for both clinical and commercial production.

These assets, along with Moderna’s network of domestic and overseas government and commercial collaborators, allowed for the rapid development of one of the world’s most effective COVID-19 vaccines.

The other therapeutics and vaccines in the company’s pipeline are targeting infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases. Moderna has 23 development programs underway across these therapeutic areas.


Market cap: US$90.71 billion

Immunotherapy company BioNTech is advancing novel therapies for serious diseases such as cancer. The company combines computational discovery and therapeutic drug platforms to rapidly develop new biopharmaceutical products. BioNTech’s portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, chimeric antigen receptor T cells, bispecific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

In addition to its diverse oncology pipeline, the company is best known today for its mRNA vaccine development and in-house manufacturing capabilities. In addition to its COVID-19 vaccine, created along with partner Pfizer (NYSE:PFE), BioNTech is also engaged in collaborative partnerships aimed at assembling mRNA vaccine candidates for a range of infectious diseases.

3. Intellia Therapeutics (NASDAQ:NTLA)

Market cap: US$11.78 billion

Intellia Therapeutics is clinical-stage genome-editing company with a strong IP portfolio based on the potential of CRISPR/Cas9 technology to create novel genetic therapeutics.

Intellia’s in vivo programs use proprietary delivery technology to intravenously administer CRISPR therapeutics and enable highly precise editing of disease-causing genes directly within specific target tissues. The company’s ex vivo programs use CRISPR technology to remove, re-engineer and reinfuse the patient’s own cells to treat cancer and autoimmune diseases.

4. Prothena (NASDAQ:PRTA)

Market cap: US$2.65 billion

Prothena is a late-stage clinical company with a growing pipeline of novel therapeutics built on decades of research on protein dysregulation expertise. This includes both wholly owned and partnered programs targeting rare peripheral amyloid and neurodegenerative diseases, such as AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases.

Recently, Prothena received US$80 million from Bristol Myers Squibb (NYSE:BMY) for the exclusive US license to PRX005, with the option for global rights after an already initiated Phase 1 study. PRX005 is an investigational anti-tau antibody targeting the microtubule binding region of tau for the treatment of Alzheimer’s disease. Tau is a microtubule-associated protein that aggregates and hyper-phospohrylates in the brains of individuals with Alzheimer’s disease to form pathological neurofibrillary tangles.

5. Protagonist Therapeutics (NASDAQ:PTGX)

Market cap: US$2.13 billion

Protagonist Therapeutics, another of the top stem cell companies, is a clinical-stage biopharmaceutical company that uses a proprietary technology platform to discover and develop novel peptide-based drugs to address significant unmet medical needs. Its pipeline includes rusfertide (PTG-300), an investigational, injectable hepcidin mimetic that is currently in a Phase 2 proof-of-concept clinical trial for polycythemia vera, a type of blood cancer; rusfertide is also in a Phase 2 study in polycythemia vera subjects with high hematocrit levels and a Phase 2 study for hereditary hemochromatosis.

The company plans to initiate a global Phase 3 randomized, placebo-controlled trial evaluating the efficacy and safety of a subcutaneously self-administered dose of rusfertide.

Protagonist also has a worldwide license and collaboration agreement with Janssen Biotech for the development of oral peptide IL-23 receptor antagonists.

6. Celldex Therapeutics (NASDAQ:CLDX)

Market cap: US$2.1 billion

Celldex Therapeutics is a clinical-stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address underserved or unserved inflammatory diseases and many forms of cancer. The company’s pipeline includes antibody-based therapeutics that have the ability to engage a patient’s immune system and/or directly inhibit tumors.

Celldex recently reported positive data from an ongoing Phase 1b study of CDX-0159 in treating chronic inducible urticaria, an inflammatory skin disease. The study showed that CDX-0159 safely depletes mast cells, which indicates the therapeutic candidate’s potential to treat a myriad of diseases with mast cell involvement. The positive data helped the company complete a US$287.5 million follow-on offering that will support the expansion of the CDX-0159 program into later-stage studies.

7. Ocugen (NASDAQ:OCGN)

Market cap: US$1.58 billion

As its name suggests, Ocugen is focused on the development and commercialization of gene therapies to cure blindness diseases. The top stem cell company’s breakthrough modifier gene therapy platform is targeting the treatment of multiple underserved retinal diseases — including wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy — with one drug.

Ocugen is also co-developing Bharat Biotech’s COVAXIN vaccine candidate for COVID-19 in the US and Canadian markets.

8. Anavex (NASDAQ:AVXL)

Market cap: US$1.4 billion

Avanex is a biopharmaceutical company developing therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system diseases, plus pain and cancer.

The company’s lead drug candidate is ANAVEX®2-73 (blarcamesine), an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. The company has completed a Phase 2a clinical trial for Alzheimer’s disease; a Phase 2 proof-of-concept study in Parkinson’s disease dementia; and a Phase 2 study in adult patients with Rett syndrome. Anavex was awarded a research grant from the Michael J. Fox Foundation for Parkinson’s Research.

During preclinical studies, ANAVEX®2-73 exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional central nervous system disorders, including epilepsy.

9. Enochian Biosciences (NASDAQ:ENOB)

Market cap: US$323.66 million

Biopharmaceutical company Enochian Biosciences is focused on developing gene-modified cellular and immune therapies to potentially cure and treat deadly diseases. Its platforms can potentially be applied to multiple indications, including HIV/AIDS, hepatitis B, corona and influenza viruses as well as cancer.

The company’s pipeline includes its lead candidate, ENO-1001, which is in preclinical development to treat HIV/AIDS as a vaccine. Another compound Enochian is working on is ENO-4001 to prevent the relapse of colon cancer. The US Food and Drug Administration has accepted a pre-investigational new drug request from Enochian for a potential cure for hepatitis B virus infection.

10. Cellect Biotechnology (NASDAQ:APOP)

Market cap: US$15.65 million

Israel-based Cellect Biotechnology is developing ApoGraft, a technology platform that functionally selects stem cells from any given tissue to enhance the safety of regenerative medicine and stem cell therapies. The technology allows for the safe and inexpensive production of cell-based therapies.

Cellect, another of the NASDAQ’s top stem cell companies, believes its process will provide researchers, clinicians and pharmaceutical companies with the ability to rapidly produce cell-based treatments and procedures in a broad range of regenerative medicine applications. The company’s lead product is aimed at bone marrow transplantations in cancer treatment.

This is an updated version of an article first published on the Investing News Network in 2017.

Don’t forget to follow us @INN_LifeScience for real-time news updates!

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

Top NASDAQ Genetics Stocks

What are the top NASDAQ genetics stocks year-to-date? We run through the five biggest gainers so far this year.

Click here to read the latest top NASDAQ genetics stocks article.

The genetics sector supports every other life science industry, with one of its contributions being the discovery of new genetic drivers of diseases.

read more Show less

The genetics industry provides data that life science companies need to make new products. Here’s a look at the largest genetics stocks.

From diagnostics to drug development, the genetics industry provides information that biotechnology, pharmaceutical and medical device companies need to continue making innovative products. The largest genetics stocks are responsible for these advances.

That’s why we’re counting down some significant players in genetics and genomics — companies that splice and edit their days away, developing technologies and tests that are key for the life science sector.

read more Show less

Which gene therapy stocks should be on investors’ radar? Here are five companies developing a wide range of gene therapy products.

For life sciences investors, the gene therapy market is one of the most interesting plays available today.

The US National Library of Medicine defines gene therapies as specialized treatments that use genes for the prevention or treatment of disease. Gene therapies are designed to help patients by inserting a gene into a cell rather than treating the patient with drugs or surgeries.

read more Show less
text saying "top stories this week"

Catch up and get informed with this week's content highlights from Charlotte McLeod, our editorial director.

Top Stories This Week: Powell Gets Fed Nomination, Using Gold in a Market Correction youtu.be

We're back after a break last week with quite a bit to cover in the gold space.

After running up past the US$1,860 per ounce mark midway through November, the yellow metal has taken a tumble. At the time of this writing on Friday (November 26) afternoon, it was sitting just under US$1,790.

Gold's losses this week have been attributed to elements like a stronger US dollar and better Treasury yields, although Jerome Powell's US Federal Reserve chair renomination has pulled other factors into play — some market watchers believe he may move to taper and raise interest rates faster than anticipated.

If the Fed follows its previously laid out timeline for tapering, it will wrap up in mid-2022; the central bank has said it won't raise rates until after that. It has also emphasized that its roadmap may change if necessary.

Looking at the larger picture for gold, I heard recently from Nick Barisheff of BMG Group, who believes the stock market is due for a major correction.

"The market is due for a major correction. What will cause it and when it will happen is anybody's guess — it could be tomorrow, it could be six months from now" — Nick Barisheff, BMG Group

It's impossible to know when this correction will happen, but Nick emphasized the importance of acting before it's too late. He pointed out that investors are typically slow to get out of the market once a crash actually begins — they wait for a turnaround, and by the time it's clear there won't be one, they've experienced big losses.

In his opinion, the solution is to get out of the stock market early and transfer money into gold.

Here's how Nick explained it:

"Instead of taking your money off the table and going into cash … you go to gold (because cash is devaluing daily). Gold will at least hold its own and probably appreciate … so by sitting it out in gold you can wait until the market finishes correcting and then buy back in" — Nick Barisheff, BMG Group

With gold's future in mind, we asked our Twitter followers this week what price they think the metal will be at the end of 2021. By the time the poll closed, most respondents had voted for the US$1,800 to US$1,900 range.

We'll be asking another question on Twitter next week, so make sure to follow us @INN_Resource or follow me @Charlotte_McL to share your thoughts.

Finally, in the cannabis space, INN's Bryan Mc Govern spoke with Dan Ahrens of AdvisorShares to get his thoughts on 2021 trends and what's ahead in 2022.

Dan was candid, and said if he had to choose one word to describe the cannabis market in 2021, it would be "painful." Like many others, he's been disappointed in the industry's performance — while positivity initially ran high due to excitement about potential federal changes in the US, ultimately progress has been slow.

"Cannabis started with a big run-up in January and February ... and things dragged from there" — Dan Ahrens, AdvisorShares

Still, Dan has hope for 2022 and said it will be a "huge year" for cannabis. He believes US reforms will come sooner rather than later, and in his opinion those widely anticipated changes will bring a wave of M&A activity.

Specifically, he expects to see alcohol, tobacco and other consumer packaged goods companies making deals with cannabis players, not just cannabis entities doing transactions with each other.

"Those big alcohol companies, tobacco companies, other consumer packaged goods product companies — they're waiting. They're waiting on the US" — Dan Ahrens, AdvisorShares

Want more YouTube content? Check out our YouTube playlist At Home With INN, which features interviews with experts in the resource space. If there's someone you'd like to see us interview, please send an email to cmcleod@investingnews.com.

And don't forget to follow us @INN_Resource for real-time updates!

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

cannabis plant layered with German flag graphic
Dmytro Tyshchenko / Shutterstock

Catch up on some of the biggest news of the week for the cannabis investment world.

Three political parties have formed a coalition in Germany, leading to a new government, and it has promised cannabis reform in the European nation.

Meanwhile, a popular cannabis retailer confirmed consumers will now find its products available for delivery on the Uber Eats mobile application in Ontario.

Keep reading to find out more cannabis highlights from the past five days.

Coalition of parties promises forward-looking cannabis policy

Germany, a country with comprehensive and elaborate medicinal rules for cannabis, is in a time of transition as a new government is set to begin to take over after 16 years of Angela Merkel.

Olaf Scholz, the proposed next chancellor of Germany, leads a three party coalition that will become the country's governing body. As part of its promises, talk of adult-use cannabis regulation has now gained even more momentum. A report from MJBizDaily quotes a German policy document that shows the coalition's stance:

"We are introducing the controlled distribution of cannabis to adults for consumption purposes in licensed shops. This controls the quality, prevents the transfer of contaminated substances and guarantees the protection of minors."

However, despite the promise and excitement, it remains to be seen how these ideas will be applied since no formal regulations have been drafted or approved yet.

Canadian cannabis retailer partners with popular delivery app

Tokyo Smoke, a cannabis retail operator in Canada owned by Canopy Growth (NASDAQ:CGC,TSX:WEED), announced a collaboration agreement with Uber Canada (NYSE:UBER) whereby cannabis consumers will be able to use the Uber Eats app to order products before they visit stores.

While the app won't let consumers get cannabis delivered to them, this new method opens the doors to more dynamic ways of buying cannabis.

"As a market leader in innovation and a platform used by so many Canadians, we believe this is the ideal next offering that can be done safely and conveniently on the Uber Eats app," Mark Hillard, vice president of operations with Tokyo Smoke, said in a press release.

A report from the Canadian Press indicates Ontario is considering allowing dispensaries to have delivery and pickup options made available to consumers permanently. The province allowed some of these purchasing options at the outset of the COVID-19 pandemic, but then removed them.

Lola Kassim, general manager of Uber Eats Canada, said this new end-to-end experience will provide consumers with responsible access to legal cannabis products.

Cannabis company news

  • Organigram Holdings (NASDAQ:OGI,TSX:OGI) issued financial results for its Q4 2021 period. In its report, the company notes a net loss of C$26 million despite a 22 percent uptick in net revenue to C$24.9 million. Beena Goldenberg, the newly appointed CEO of the firm, is encouraged by the market share position earned by the company, which said it became the fourth biggest producer in Canada during the reporting period.
  • Halo Collective (NEO:HALO,OTCQB:HCANF) confirmed the decision for Akanda, its spinoff company focused on international cannabis opportunities, to begin trading on a US exchange. "The number of shares to be offered and the price range for the proposed offering have not yet been determined," the company told investors in a press release.
  • High Tide (NASDAQ:HITI,TSXV:HITI) announced the acquisition of 80 percent of NuLeaf Naturals, a CBD product wellness developer, for an estimated US$31.24 million. The deal includes a three year option clause for High Tide to complete a total acquisition. "As international markets open up and as export regulations evolve, NuLeaf's cGMP-certified facility positions us to take advantage of the global CBD business opportunity," Raj Grover, president and CEO of High Tide, said.
  • Humble & Fume (CSE:HMBL,OTC Pink:HUMBF) released the financial report for its first 2022 fiscal quarter to shareholders and the market. "As the legal cannabis market in North America continues to mature, Humble remains agile and focused on providing a leading solution for brands to scale quickly and retailers to focus on their customers," Joel Toguri, CEO of Humble, said.

Don't forget to follow us @INN_Cannabis for real-time updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.


S&P 5004594.62-106.84


Heating Oil2.09-0.29
Natural Gas5.49+0.43